Trefwoorden
Meer tonen Trefwoorden
Inhoudsopgave
  1. 1. Klinische studie
  2. 2. Routinedocumentatie
  3. 3. Register-/kohortstudies
  4. 4. Kwaliteitswaarborging
  5. 5. Datastandaard
  6. 6. Patiëntenvragenlijst
  7. 7. Medisch vakgebied
Geselecteerde datamodellen

U moet ingelogd zijn om meerdere datamodellen te selecteren en die te downloaden of te analyseren.

4758 Zoekresultaten.
Relevantie Beoordeling Nieuwe eerst Oude eerst

register Finish Cancer Registry cancer - register

- 15-03-21 - 1 Formulier, 6 Itemgroepen, 49 Data-elementen, 2 Talen
Itemgroepen: CancerRegistry, Previous cancer, Current Neoplasm, Treatment, surgery, radiotherapy
Data set from the Finish cancer registry, with friendly permission (http://www.cancer.fi/syoparekisteri/en/registration/forms-and-instructions/)

Breast Cancer NCT00433589 Treatment - Endocrine therapy - 2498727v1.0 - Endocrine therapy

- 09-01-15 - 1 Formulier, 3 Itemgroepen, 14 Data-elementen, 1 Taal
Itemgroepen: Header, Endocrine therapy, Footer Module
Endocrine therapy Genetic Testing or Clinical Assessment in Determining the Need for Chemotherapy in Women With Breast Cancer That Involves No More Than 3 Lymph Nodes Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=19677A9A-FFBD-2E6F-E044-0003BA3F9857

Pancreatic Cancer NCT00058149 Quality of Life - Brief Pain Inventory - 2031356v3.0 - Brief Pain Inventory

- 09-01-15 - 1 Formulier, 2 Itemgroepen, 23 Data-elementen, 1 Taal
Itemgroepen: Header, CCRR MODULE
Brief Pain Inventory A Phase III, Randomized Study of Gemcitabine (Fixed-Dose Rate Infusion) and Oxaliplatin (NSC 266046) Versus Gemcitabine (Fixed-Dose Rate Infusion) Versus Gemcitabine (30-Minute Infusion) in Pancreatic Carcinoma Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=AE65F8E1-704E-30A0-E034-0003BA12F5E7

Breast Cancer Adverse Event NCT00382070 - rade 2 and 3 Adverse Event Report Breast Cancer NCT00382070 NSABP B-42

- 20-09-21 - 1 Formulier, 2 Itemgroepen, 9 Data-elementen, 1 Taal
Itemgroepen: Header, Adverse event
NSABP Protocol B-42 - Grade 2 and 3 Adverse Event (AE) Report Form Worksheet Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer NCT00382070 Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=17ADF05F-DB75-341D-E044-0003BA3F9857

dbGaP phs000694 Clinical Cancer Sequencing - pht003754.v3.p2

- 29-01-25 - 4 Formulieren, 1 Itemgroep, 2 Data-elementen, 1 Taal
Itemgroep: pht003754
Principal Investigator: Levi Garraway, Dana Farber Cancer Institute, Boston, MA, USA MeSH: Neoplasms https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000694 Translating whole exome sequencing (WES) for prospective clinical use may impact the care of cancer patients; however, multiple innovations are necessary for clinical implementation. These include: (1) rapid and robust WES from formalin-fixed paraffin embedded (FFPE) tumor tissue, (2) analytical output similar to data from frozen samples, and (3) clinical interpretation of WES data for prospective use. In this study, we describe a prospective clinical WES platform for archival FFPE tumor samples. The platform employs computational methods for effective clinical analysis and interpretation of WES data. When applied retrospectively to 511 exomes, the interpretative framework revealed a "long tail" of somatic alterations in clinically important genes. Prospective application of this approach identified clinically relevant alterations in 15/16 patients. Overall, this methodology may inform the widespread implementation of precision cancer medicine.

pht003755.v3.p2

1 Itemgroep 3 Data-elementen

pht003757.v3.p2

1 Itemgroep 3 Data-elementen

pht003756.v3.p2

1 Itemgroep 2 Data-elementen

Follow-Up - Follow-Up Oncology

- 02-11-15 - 1 Formulier, 5 Itemgroepen, 16 Data-elementen, 19 Talen
Itemgroepen: Identity, Diagnosis, Therapy, Study, Follow-up
Follow Up Dokumentation zur automatischen Berechnung von Kaplan-Meier Kurven.

dbGaP phs000602 Identification of Targetable FGFR Gene Fusions in Diverse Cancers - Eligibility

- 11-11-22 - 4 Formulieren, 1 Itemgroep, 19 Data-elementen, 1 Taal
Itemgroep: IG.elig
Principal Investigator: Arul M. Chinnaiyan, MD, PhD, University of Michigan, MI, USA MeSH: Neoplasms,Cholangiocarcinoma,Breast Neoplasms,Prostatic Neoplasms,Urinary Bladder Neoplasms,Mouth Neoplasms https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000602 In this study, patients with advanced cancer across all histologies were enrolled in our IRB approved clinical sequencing program, called MI-ONCOSEQ, to go through an integrative sequencing which includes whole exome sequencing of the tumor and matched normal, and transcriptome sequencing. Four index cases were identified which harbor gene rearrangements of FGFR2 including two cholangiocarcinoma cases, a metastatic breast cancer case, and a metastatic prostate cancer case. After extending our assessment of FGFR rearrangements across multiple tumor cohorts, including TCGA, we identified FGFR gene fusions with intact kinase domains of FGFR1, FGFR2, or FGFR3 in cholangiocarcinoma, breast cancer, prostate cancer, lung squamous cell cancer, bladder cancer, thyroid cancer, oral cancer, glioblastoma, and head and neck squamous cell cancer. All FGFR fusion partners tested exhibit oligomerization capability, suggesting a shared mode of kinase activation. Overexpression of FGFR fusion proteins in vitro induced cell proliferation, and bladder cancer cell lines that harbors FGFR3 fusion proteins exhibited enhanced susceptibility to pharmacologic inhibition in vitro and in vivo. Due to the combinatorial possibilities of FGFR family fusion to a variety of oligomerization partners, clinical sequencing efforts which incorporate transcriptome analysis for gene fusions are poised to identify rare, targetable FGFR fusions across diverse cancer types.

pht003221.v1.p1

1 Itemgroep 5 Data-elementen

pht003222.v1.p1

1 Itemgroep 6 Data-elementen

pht003220.v1.p1

1 Itemgroep 5 Data-elementen

dbGaP phs000487 Functionally Active Copy Number Variants Associated with Prostate Cancer Risk - Eligibility

- 29-01-25 - 5 Formulieren, 1 Itemgroep, 1 Data-element, 1 Taal
Itemgroep: IG.elig
Principal Investigator: Francesca Demichelis, PhD, Centre for Integrative Biology, University of Trento, Trento, Italy MeSH: Prostatic Neoplasms https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000487 Prostate cancer is a leading cause of cancer death in males throughout the world and has the largest estimated effect of heritability among the most common tumor types. Copy Number Variants (CNVs) are a recently recognized class of human germline polymorphisms (Iafrate AJ, et al. (2004) Nat Genet 36, 949-951; Sebat J, et al. (2004) Science 305, 525-528.) and are associated with a variety of human diseases, including cancer. This study characterized 1,903 individuals from the Tyrol Early Prostate Cancer Detection Program (Bartsch G, et al. (2008) BJU Int 101, 809-816) using a computational framework (Banerjee S, et al. (2011) PLoS One 29;6(3)). The study results establish non-coding and coding germline CNVs as significant risk factors for prostate cancer susceptibility and implicate their role in disease development and progression. The study "Identification of functionally active, low frequency copy number variants at 15q21.3 and 12q21.31 associated with prostate cancer risk," Demichelis F, Setlur SR, Proc Natl Acad Sci U S A. 2012 Apr 24;109(17):6686-91.

pht002923.v1.p1

1 Itemgroep 5 Data-elementen

pht002924.v1.p1

1 Itemgroep 5 Data-elementen

pht002925.v1.p1

1 Itemgroep 7 Data-elementen

pht003118.v1.p1

1 Itemgroep 5 Data-elementen

EORTC QLQ_C30 - EORTC QLQ_C30 MS University Hospital Muenster (UKM)

- 07-11-17 - 1 Formulier, 1 Itemgroep, 3 Data-elementen, 1 Taal
Itemgroep: General information
Used as Hospital Routine Documentation Form at the University Hospital Muenster. Original Form name: EORTC QLQ-C30 MS. Copyright: 1995 EORTC Quality of Life Group. All rights reserved. Version 3.0 German description: EORTC QLQ-C30 (version 3.0) Wir sind an einigen Angaben interessiert, die Sie und Ihre Gesundheit betreffen. Bitte beantworten Sie die folgenden Fragen selbst, indem Sie die Zahl ankreuzen, die am besten auf Sie zutrifft. Es gibt keine "richtigen" oder "falschen" Antworten. Ihre Angaben werden streng vertraulich behandelt.

dbGaP phs001075 Sequencing to Guide Cancer Care (CanSeq) - pht006108.v1.p1

- 23-06-23 - 4 Formulieren, 1 Itemgroep, 3 Data-elementen, 1 Taal
Itemgroep: pht006108
Principal Investigator: Levi Garraway, Dana Farber Cancer Institute, Boston, MA, USA MeSH: Neoplasms,Colonic Neoplasms,Lung Neoplasms,Adenocarcinoma of lung https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001075 The overall goal of the CanSeq U01 project is to study the impact of whole-exome sequencing (WES) on the clinical care of cancer patients and oncology provider practices. The aims of Project 1 are to implement and establish the feasibility of germline and somatic WES in patients with advanced solid tumors (lung and colon); to develop a framework for interpreting and reporting for exome sequencing data; to determine the proportion of patients with "actionable items" compared to existing technologies; and to report on the percentage of patients in whom unique WES findings led to a clinical action. The aims of Project 2 are to implement a production-scale platform for WES from archival (FFPE) material; to identify biologically relevant somatic and germline alterations existing in tumor/normal DNA from individual patients; to produce an evidence-based list of clinically "actionable" genetic alterations; and to develop inferential models that predict the utility of tumor genomic data within the larger clinical context. The goals of Project 3 are to describe the impact of information derived through WES on cancer patients; to test the hypothesis that patients will want to receive information about all potentially informative somatic and germline variants; to study patients' understanding of disclosed genomic information; and to describe the experiences of oncology providers as they implement WES into cancer care delivery.

pht006109.v1.p1

1 Itemgroep 3 Data-elementen

pht006111.v1.p1

1 Itemgroep 3 Data-elementen

pht006110.v1.p1

1 Itemgroep 2 Data-elementen

Radiation Therapy Oncology Group Initial Follow-up Form Phase III Lung Prophylactic Cranial RT NCT00048997

- 20-09-21 - 1 Formulier, 3 Itemgroepen, 46 Data-elementen, 1 Taal
Itemgroepen: Header Module, Medical history, Comments
Radiation Therapy Oncology Group Initial Follow-up Form Phase III Lung Prophylactic Cranial RT Radiation Therapy in Preventing CNS Metastases in Patients With Non-Small Cell Lung Cancer NCT00048997 Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=9EC372A6-7094-05D5-E034-080020C9C0E0

Southwest Oncology Group Registration Form

- 20-09-21 - 1 Formulier, 4 Itemgroepen, 30 Data-elementen, 1 Taal
Itemgroepen: SWOG clinical trial administrative data, patient demographics, Notes, CCRR MODULE
Southwest Oncology Group Registration Form Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=A4CF746B-17EF-3705-E034-080020C9C0E0

Contact

Gebruik dit formulier voor feedback, vragen en verbeteringsvoorstellen.

Velden gemarkeerd met een * zijn verplicht.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial